| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:16641546 | IVR | 15000 mg/L | 15000 mg/L | Decreased thymus gland weights in offspring | Developmental endocrine-mediated perturbations;Immunological endocrine-mediated perturbations |
| IVR | 15000 mg/L | 15000 mg/L | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased spleen weights in offspring | Developmental endocrine-mediated perturbations;Immunological endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased brain weights in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased uterine weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased weights of thyroid gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased weights of pituitary gland in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Decreased uterine weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Decreased weights of adrenal gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Decreased testosterone levels | Reproductive endocr | |
| IVR | 600 mg/L | - | No significant effects observed | ||
| IVR | 15000 mg/L | 15000 mg/L | Alterations in vaginal opening | ||
| IVR | 15000 mg/L | 15000 mg/L | Decreased weights of epididymis | ||
| IVR | 15000 mg/L | 15000 mg/L | Increased weights of seminal vesicles in offspring | ||
| PMID:16750591 | IVR | 10 mg/kg/day | 10 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects morphology of hepatocytes | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects morphology of hepatocytes | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased hepatic glycogen levels | Hepatic endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased Acid phosphatase (ACP) activity in the liver | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased hepatic glycogen levels | Hepatic endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-medi | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased cholesterol levels | ||
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects liver function | ||
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased hepatic glycogen levels | ||
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects morphology of hepatocytes | ||
| IVR | 50 mg/kg/day | 50 mg/kg/day | Oxidative stress in liver | ||
| IVR | 50 mg/kg/day | 50 mg/kg/day | Changes in liver morphology | ||
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased Lactate dehydrogenase (LDH) levels | ||
| PMID:24449359 | IVR | 3 mg/kg | 3 mg/kg | Testicular inflammation | Reproductive endocrine-mediated perturbations |
| PMID:24994688 | IVR | 100 mg/kg | 100 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.001 M | 0.00005 - 0.001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.001 M | 0.00005 - 0.001 M | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:25554385 | IVR | 0.174 mg/kg/day | 0.174 mg/kg/day | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 0.174 mg/kg/day | 0.174 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:27513369 | IVTH | 0.00004 - 0.0004 M | 0.00004 - 0.0004 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00004 - 0.0004 M | 0.00004 - 0.0004 M | Increase in estradiol/testosterone ratio | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00004 - 0.0004 M | 0.00004 - 0.0004 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:31085347 | IVR | 10 mg/kg/day | 10 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:33983380 | IVR | 75 mg/kg/day | 75 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations |
| PMID:34129163 | IVR | 3 mg/kg | 3 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:34678933 | IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| PMID:37942807 | IVR | 1 mg/kg/day | 1 mg/kg/day | Induce apotosis in adipocytes | Metabolic endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased adipose tissue weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Altered adipocyte function | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Altered adipocyte morphology | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.